Retina Synthesis

Join these renowned experts for a panel discussion on how to incorporate into clinical practice the latest treatments for neovascular age-related macular degeneration (nAMD). The panelists will also share the latest outcomes data and their clinical experience using these therapies.

We review the current status of the Ocular Therapeutics TKI sustained release delivery system for treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology USC Roski Eye Institute.

We review current status of clinical research on gene therapy for neovascular AMD and diabetic retinopathy with Dr. Allen Ho, Professor of Ophthalmology, Jefferson Medical College and Wills Eye Hospital.

We review long term results of the Port Delivery System for treating neovascular AMD  with Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida.

We review the results of the phase I Graybug study Altissimo using sustained release tyrosinase kinase inhibitor for long term treatment of neovascular AMD with Dr. Veeral Sheth, Chicago, Illinois, Assistant Clinical Professor University of Illinois at Chicago.

The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.

We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.

We review the results of the KS-301 wet macular degeneration trial with Dr. Carl Regillo, Chief of the Retina Service at Wills Eye Hospital

Phase I results of suprachoroidal delivery of a gene vector in treating neovascular AMD are promising. A discussion with Nikolas London, MD from  Retina Consultant Group in San Diego CA & Scripps Memorial Hospital La Jolla. 

Discussion of variations in injection volume for treatment of nAMD, DME and MERVO with Roger Goldberg, M.D., M.B.A.,  Bay Area Retina Associates

We examine the role of residual IRF and SRF in visual acuity results in treating nAMD. Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida reviews the results of the Hawk and Harrier trials.

We discuss the use of the newly approved Susvimo system for sustained delivery of ranibizumab in the treatment of neovascular AMD with Carl Regillo, MD, Professor of Ophthalmology Thomas Jefferson University and Director of the Retina Service at the Wills Eye Hospital.

We discuss the pathophysiology and techniques associated with subchoroidal administration of drugs and gene therapy vectors with James Major, MD, Ph. D., Retina Consultants of Texas and Houston Methodist Hospital.

We discuss the newly approved Xipere system for suprachoroidal administration of triamcinolone for treatment of macular edema associated with uveitis with Dr. Steven Yeh

In our latest update, We discuss clinical and business careers with Pravin Dugel MD, President, of Iveric Bio.

We discuss with David Lally, MD   Springfield, Ma. Assistant Professor at University of Massachusetts and Tufts the use of elamipretide, a novel agent which acts at the level of the mitochondria in the treatment of geographic atrophy.

We discuss with Dr. Christoper Reimann of the Cincinnati Eye Institute the results of an early phase clinical trial in which stem cell derived retina pigment epithelial cells are injected into the sub retinal space in the maculas of eyes with geographic atrophy.

We discuss the use of suprachoroidal gene therapy for eyes with diabetic retinopathy without macular edema with Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia.

We review surgical techniques for sub retinal gene therapy with Dr. Lejla Vajzovic.

Dr. Yasha Modi, Associate Professor of Ophthalmology at the NYU Langone Medical Center provides an evidence based review of management of retinal venous occlusion.

We discuss the use of a cooling probe as primary anesthesia for intravitreal injection with Ajay Kuriyan, MD, Associate Professor of Ophthalmology, Wills Eye Hospital.

We discuss blockade of complement component C1q as a novel treatment for geographic atrophy with Donald Fong, MD, Vice President Ophthalmology Clinical Development, Annexon.

We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.

We asked Dr. Mohamed Genead, Chief Medical Officer, Nanoscope Therapeutics to discuss and review the latest developments in optogenetic gene therapy for retinal degenerations. 

Dr. Robert Avery of California Retina Consultants reviews the latest status of gene therapy for AMD and DR.